Literature DB >> 7469857

Salmon-patch hemorrhages after central retinal artery occlusion in sickle cell disease.

L M Jampol, P Condon, R Dizon-Moore, G Serjeant, J A Schulman.   

Abstract

In two patients with sickle cell disease (one hemoglobin SC and one hemoglobin SS), central retinal artery occlusions developed. In one case, the occlusion followed a retrobulbar injection of lidocaine hydrochloride. Although the central retinal artery reperfused in each patient, many secondary peripheral retinal arteriolar occlusions remained. During the subsequent days, multiple salmon-patch hemorrhages developed in the distribution of these occluded arterioles. In one patient, the salmon-patch hemorrhages evolved into atrophic schisis cavities. These unusual cases allowed us to document the origin of salmon-patch hemorrhages after peripheral retinal arteriolar occlusions. The development of the hemorrhages was a delayed phenomenon that occurred hours to days after the initial vascular occlusion. Reperfusion of the damaged ischemic vessels with a blowout of the wall of the vessels seems the most likely explanation for this phenomenon.

Entities:  

Mesh:

Year:  1981        PMID: 7469857     DOI: 10.1001/archopht.1981.03930010239002

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Why retrobulbar anesthesia?

Authors:  W C Petersen; M Yanoff
Journal:  Trans Am Ophthalmol Soc       Date:  1990

2.  Shape determinations of ribosomal proteins in situ.

Authors:  K H Nierhaus; R Lietzke; R P May; V Nowotny; H Schulze; K Simpson; P Wurmbach; H B Stuhrmann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

3.  Recurrent visual loss in homozygous sickle cell disease.

Authors:  P I Condon; R A Whitelocke; A C Bird; J F Talbot; G R Serjeant
Journal:  Br J Ophthalmol       Date:  1985-09       Impact factor: 4.638

4.  Sickle cell retinopathy in young children in Jamaica.

Authors:  J F Talbot; A C Bird; G R Serjeant; R J Hayes
Journal:  Br J Ophthalmol       Date:  1982-03       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.